Flore Sicre de Fontbrune on Muck Rack

Flore Sicre de Fontbrune

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Flore Sicre

Contact Flore Sicre, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Upfront alemtuzumab-based MUD HSCT in childhood aplastic anemia: excellent survival and GRFS, but immune challenges persist

|
By Audrey Petit, Arthur Sterin, Virginie Gandemer, Claire Goudet, Mony Fahd, Bénédicte Bruno, Nimrod Buchbinder, Cécile Pochon, Fanny Rialland, Elodie Lainey, Lise Larcher, Ibrahima Ba, Marie Robin, Jacques-Emmanuel Galimard, Jean-Hugues Dalle, Regis de Latour, Cécile Renard, Flore Sicre de Fontbrune, Gaëlle Stofleth, Marie Angoso, Stéphanie Nguyen-Quoc
| Nature Verified
Acquired aplastic anemia (aAA) an immune-mediated bone marrow failure, where the balance between curative hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) continues to evolve. In children lacking a matched related donor (MRD), horse antithymocyte globulin plus cyclosporine (CSA) remains the standard first-line therapy, achieving 70% hematologic responses and >80% overall survival (OS) at 5 years [1, 2].
Open in Who Shared Issue with article?

Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective study

|
By Jan Styczynski, Gloria Tridello, Inge Verheggen, Nina Knelange, Lotus Wendel, Per Ljungman, José Luis Piñana, Malgorzata Mikulska, Lidia Gil, Simone Cesaro, Fabio Ciceri, Raffaella Greco, Depei Wu, Didier Blaise, Raffaella Cerretti, Patrice Chevallier, Edouard Forcade, Flore Sicre de Fontbrune, Mohamad Mohty Verified, Claude Eric Bulabois, Stéphanie Nguyen Quoc, Ibrahim Yakoub-Agha, Rafael de la Camara, Dina Averbuch, Sophie Ducastelle Lepretre
| Nature Verified
Allogeneic hematopoietic cell transplantation (allo-HCT), including haploidentical HCT (haplo-HCT) is a potentially curative therapy that shows encouraging long-term outcomes in hematological diseases [1,2,3,4]. In prior studies and meta-analyses, donor and recipient Epstein-Barr virus (EBV) seropositivity has been shown to significantly impact transplant outcomes after allo-HCT [5,6,7,8].
Open in Who Shared Issue with article?

Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults

|
By Gabriel Aleixo, Jiayin Zheng, Jimmy Lee, Eleonore Kaphan, Wei-Ying Jen, Mia Djulbegovic, Jairo Matthews, Tapan M Kadia, Timothy Olson, Regis de Latour, Flore Sicre de Fontbrune, Taha Bat, Courtney DiNardo, Daria V. Babushok, HeeJin Cheon, Stephanie Soewito, Neha Kalakuntla, Sumasri Kotha, Alex Rupsee
| Nature Verified
Abstract Acquired aplastic anemia (AA) can present similarly to inherited bone marrow failure syndromes (IBMFS) but treatment differs. AA diagnosis relies on excluding IBMFS; however, genetic testing is not always available, may delay care or be inconclusive. We developed the Predictive Aplastic Score System (PASS), a clinical tool using readily available data to distinguish AA from IBMFS in adults. The training cohort included 212 adults (162 AA, 50 IBMFS).
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified